The potential of cystatin-C to evaluate the prognosis of acute heart failure: A comparative study

References

• Triposkiadis F, Starling RC, Boudoulas H, Giamouzis G, Butler J.The cardiorenal syndrome in heart failure: Cardiac? renal? syndrome?Heart Fail Rev.2012;17:355–66.
   PubMed Web of Science ®Google Scholar
• Harinstein ME, Filippatos GS, Gheorghiade M.Acute heart failure syndromes: Epidemiology, risk stratification and prognostic factors.Acute Card Care2009;11:77–82.
   PubMedGoogle Scholar
• Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al.ADHERE Scientific Advisory Committee and Investigators: Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE).Am Heart J.2005;149:209–16.
   PubMed Web of Science ®Google Scholar
• Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, et al.Serum cystatin C measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine.Kidney Int.1995;47:312–8.
   PubMed Web of Science ®Google Scholar
• Coll E, Botey A, Alvarez L, Poch E, Quintó L, Saurina A, et al.Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment.Am J Kidney Dis.2000;36:29–34.
   PubMed Web of Science ®Google Scholar
• Deo R, Shlipak MG, Ix JH, Ali S, Schiller NB, Whooley MA.Association of cystatin C with ischemia in patients with coronary heart disease.Clin Cardiol.2009;32:E18–22.
   PubMedGoogle Scholar
• Dupont M, Wu Y, Hazen SL, Tang WH.Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events.Circ Heart Fail.2012;5:602–9.
   PubMed Web of Science ®Google Scholar
• Pérez-Calvo JI, Ruiz-Ruiz FJ, Carrasco-Sánchez FJ, Morales-Rull JL, Manzano-Fernández S, Galisteo-Almeda L, et al.Prognostic value of serum cystatin C and N-terminal pro B-type natriuretic peptide in patients with acute heart failure.Eur J Intern Med.2012;23:599–603.
   PubMed Web of Science ®Google Scholar
• Manzano-Fernández S, Januzzi JL Jr, Boronat-Garcia M, Bonaque-González JC, Truong QA, Pastor-Pérez FJ, et al. β-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure.J Am Coll Cardiol.2011;57: 849–58.
   PubMed Web of Science ®Google Scholar
• Campbell CY, Clarke W, Park H, Haq N, Barone BB, Brotman DJ.Usefulness of cystatin C and prognosis following admission for acute heart failure.Am J Cardiol.2009;104:389–92.
   PubMed Web of Science ®Google Scholar
• Lassus J, Harjola VP, Sund R, Siirilä-Waris K, Melin J, Peuhkurinen K, et al.FINN-AKVA Study group: Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP.Eur Heart J.2007; 28:1841–7.
   PubMed Web of Science ®Google Scholar
• Carrasco-Sánchez FJ, Galisteo-Almeda L, Páez-Rubio I, Martínez-Marcos FJ, Camacho-Vázquez C, Ruiz-Frutos C, et al.Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction.J Card Fail.2011;17:31–8.
   PubMed Web of Science ®Google Scholar
• Naruse H, Ishii J, Kawai T, Hattori K, Ishikawa M, Okumura M, et al.Cystatin C in acute heart failure without advanced renal impairment.Am J Med.2009;122:566–73.
   PubMed Web of Science ®Google Scholar
• Damman K, van der Harst P, Smilde TD, Voors AA, Navis G, van Veldhuisen DJ, et al.Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure.Heart2012;98:319–24.
   PubMed Web of Science ®Google Scholar
• Ruan ZB, Zhu L, Yin YG, Chen GC.Cystatin C, N-terminal probrain natriuretic peptides and outcomes in acute heart failure with acute kidney injury in a 12-month follow-up: Insights into the cardiorenal syndrome.J Res Med Sci.2014;19:404–9.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, et al.Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease.Ann Intern Med.2006;145:237–46.
   PubMed Web of Science ®Google Scholar
• Okura T, Jotoku M, Irita J, Enomoto D, Nagao T, Desilva VR, et al.Association between cystatin C and inflammation in patients with essential hypertension.Clin Exp Nephrol.2010;14:584–8.
   PubMed Web of Science ®Google Scholar
• Evangelopoulos AA, Vallianou NG, Bountziouka V, Katsagoni C, Bathrellou E, Vogiatzakis ED, et al.Association between serum cystatin C, monocytes and other inflammatory markers.Intern Med J.2012;42:517–22.
   PubMed Web of Science ®Google Scholar
• Yamashita H, Nishino T, Obata Y, Nakazato M, Inoue K, Furusu A, et al.Association between cystatin C and arteriosclerosis in the absence of chronic kidney disease.J Atheroscler Thromb.2013;20:548–56.
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, et al.Cardiovascular health study: Cystatin C concentration as a risk factor for heart failure in older adults.Ann Intern Med.2005;142:497–05.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Katz R, Fried LF, Jenny NS, Stehman-Breen C, Newman AB, et al.Cystatin-C and mortality in elderly persons with heart failure.J Am Coll Cardiol.2005;45:268–71.
   PubMed Web of Science ®Google Scholar